Dyslipidemia.
Conditions
Interventions
Intervention 1: Intervention group: They will receive standard treatment measures to correct dyslipidemia, which include statins, plus a 140mg dose of Evolocumab with brand name of Repatha as a subcut
Sponsors
Hamedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: People with history of cardiovascular diseases including ST Elevation Myocardial Infarction (STEMI), non STEMI, history of Percoutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft (CABG) fasting LDL-C equal more than 70mg/dl Age between 18 and 80 under treatment with high dose Astatins ( Atorvastatin dosage 20-40 mg or Rosuvastatnin dosage 20-40 mg) Having consent
Exclusion criteria
Exclusion criteria: History of hemorrhagic stroke Past drug history of using PCSK9 inhibitors Glumerular filtering rate (GFR) < 30% Past medical history of malignancies History of major organ transplant Pastmedical history or family history of hereditory myogenic disorders Pregnancy or breastfeeding or deciding to get pregnant Allergy to Evolocumab, not tolerating it or causing complications in the patients Patient's unwillingness to participate in the study, cooperate, or take medication correctly
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in lipid profile including Total cholesterol, TG, LDL-C, HDL-C, and LDL-C/HDL-C ratio and their achievement to target levels. Timepoint: In this study, the patient's lipid profile will be examined by tests at the beginning of the study and 12 weeks after beginning ovolacumab administeration. Method of measurement: Performing biochemical tests on the patient's blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNegin Vejdani Nozar
Hamedan University of Medical Sciences
Outcome results
None listed